Press Release | Propel Bio Partners Highlights Progress of EIT Pharma Under Leadership of CEO Dr. Leen Kawas

The FDA has accepted the New Drug Application for Lonafarnib, EIT Pharma's first-in-class oral therapy for chronic hepatitis D, following the largest clinical trial ever conducted in the disease. This release covers the company's late-stage infectious disease pipeline under Dr. Leen Kawas's leadership, including its Phase 2 program for severe acute viral respiratory infections, and why she says these programs sit exactly where the industry should be focused.

Read the Press Release Here